Skip to main content
CellaVision logo

CellaVision — Investor Relations & Filings

Ticker · CEVI ISIN · SE0000683484 LEI · 529900IUBZBZ0HXFJ114 ST Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2013-04-09 Annual Report
Country SE Sweden
Listing ST CEVI

About CellaVision

https://www.cellavision.com/

CellaVision is a medical technology company that provides digital solutions for cell morphology in hematology. The company specializes in automating and standardizing the analysis of blood and other body fluids for both human and veterinary applications. Its core offerings include a complete system of analyzers, instruments, software, and reagents designed for hematology laboratories of all sizes. By utilizing patented technology that integrates automated microscopy, advanced image analysis, and artificial intelligence, CellaVision's systems digitize the traditional manual review of blood smears. This automation enhances laboratory workflow efficiency, improves diagnostic accuracy, and facilitates remote collaboration among healthcare professionals, advancing diagnostic certainty.

Recent filings

Filing Released Lang Actions
Annual Report 2012
Annual Report Classification · 1% confidence The document is explicitly titled 'Annual Report 2012' and contains comprehensive sections typical of a full annual report, including CEO comments, financial statements, notes, audit reports, and management reports. It is a substantial document (over 270,000 characters) that provides a full year's performance review, not merely an announcement or a summary. FY 2012
2013-04-09 English
CellaVision och Beckman Coulter utökar samarbetet genom att addera EMEA till sitt globala distributionsavtal
Regulatory Filings Classification · 1% confidence The document is a press release announcing an expansion of a global distribution agreement between CellaVision and Beckman Coulter to include the EMEA region. It details a strategic business development and partnership update. This type of announcement, which concerns business operations, partnerships, and market strategy rather than specific financial results (ER/IR), management changes (MANG), or insider trading (DIRS), fits best under a general regulatory announcement or a specific category if available. Since it is a significant business development announcement released to the public market, and it is not a formal financial report (10-K, IR, ER), nor a specific filing like a proxy or dividend notice, it falls under the general category for regulatory announcements or miscellaneous filings. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, time-sensitive corporate announcement that doesn't fit a more specific operational code like MANG or CAP. The document length is short (3372 chars) and it is a direct announcement, not a report itself.
2013-04-08 Swedish
CellaVision and Beckman Coulter enhance partnership by adding EMEA to their global distribution agreement
Regulatory Filings Classification · 1% confidence The document announces an enhancement to a distribution agreement between CellaVision and Beckman Coulter, specifically adding the EMEA region. It details the business implications, market strategy, and provides contact information. The text is short (3316 characters) and concludes with a section titled 'Publication' stating when the information was released for public disclosure, which is characteristic of a formal regulatory announcement rather than a comprehensive report (like 10-K or IR). Since this is a specific business update/announcement that doesn't fit perfectly into categories like DIV, CAP, or MANG, and it is a formal disclosure, the most appropriate general category for non-standard regulatory announcements is RNS (Regulatory Filings). It is not a proxy statement (PSI), earnings release (ER), or management discussion (MDA).
2013-04-08 English
CellaVision's 2012 Annual Report now available
Annual Report Classification · 1% confidence The document is titled 'Annual Report 2012' and contains comprehensive sections including CEO comments, market overview, sustainability report, financial statements, notes, and an audit report. It provides detailed financial data, performance metrics, and strategic outlook for the fiscal year 2012. It meets the criteria for a full annual report rather than an announcement or summary. FY 2012
2013-04-03 English
CellaVision publicerar årsredovisningen för 2012
Annual Report Classification · 1% confidence The document is titled 'Årsredovisning 2012' (Annual Report 2012) for CellaVision. It contains comprehensive financial data, a management report (VD har ordet), sustainability reporting, financial statements, notes, and an auditor's report. It is clearly the full annual report for the fiscal year 2012, not an announcement or a summary. FY 2012
2013-04-03 Swedish
Notice of Annual General Meeting in CellaVision AB, April 24, 2013
AGM Information Classification · 1% confidence The document is explicitly titled "Kallelse till årsstämma i CellaVision AB (publ)" which translates to "Notice of Annual General Meeting in CellaVision AB (publ)". It details the date, time, location, registration requirements, proposed agenda (including election of board members, approval of financial statements, and decisions on remuneration/incentive programs), and dividend proposal, all standard components of a notice for an Annual General Meeting (AGM). This directly corresponds to the AGM Information category.
2013-03-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.